Contrasting Invivyd (IVVD) and The Competition

Invivyd (NASDAQ:IVVD) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Invivyd to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for Invivyd and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1	2	3	0	2.33
Invivyd Competitors	9858	15137	45528	1590	2.54

Invivyd currently has a consensus price target of $10.00, indicating a potential upside of 1,640.95%. As a group, “Biotechnology” companies have a potential upside of 99.28%. Given Invivyd’s higher possible upside, equities research analysts plainly believe Invivyd is more favorable than its rivals.

Insider and Institutional Ownership

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 12.2% of Invivyd shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Invivyd and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Invivyd Competitors	-12,285.98%	-196.04%	-30.61%

Volatility & Risk

Invivyd has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Invivyd’s rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Invivyd and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Invivyd	$53.43 million	-$52.49 million	-1.74
Invivyd Competitors	$702.95 million	$10.43 million	-15.13

Invivyd’s rivals have higher revenue and earnings than Invivyd. Invivyd is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Invivyd rivals beat Invivyd on 7 of the 12 factors compared.

About Invivyd

Invivyd, Inc. is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve. Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.